The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy
Background: Individual risk prediction of 5-year locoregional recurrence (LRR) and contralateral breast cancer (CBC) supports decisions regarding personalised surveillance. The previously developed INFLUENCE tool was rebuild, including a recent population and patients who received neoadjuvant system...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977624001607 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856886942793728 |
|---|---|
| author | M.C. Van Maaren T.A. Hueting D.J.P. van Uden M. van Hezewijk L. de Munck M.A.M. Mureau P.A. Seegers Q.J.M. Voorham M.K. Schmidt G.S. Sonke C.G.M. Groothuis-Oudshoorn S. Siesling |
| author_facet | M.C. Van Maaren T.A. Hueting D.J.P. van Uden M. van Hezewijk L. de Munck M.A.M. Mureau P.A. Seegers Q.J.M. Voorham M.K. Schmidt G.S. Sonke C.G.M. Groothuis-Oudshoorn S. Siesling |
| author_sort | M.C. Van Maaren |
| collection | DOAJ |
| description | Background: Individual risk prediction of 5-year locoregional recurrence (LRR) and contralateral breast cancer (CBC) supports decisions regarding personalised surveillance. The previously developed INFLUENCE tool was rebuild, including a recent population and patients who received neoadjuvant systemic therapy (NST). Methods: Women, surgically treated for nonmetastatic breast cancer, diagnosed between 2012 and 2016, were selected from the Netherlands Cancer Registry. Cox regression with restricted cubic splines was compared to Random Survival Forest (RSF) to predict five-year LRR and CBC risks. Separate models were developed for NST patients. Discrimination and calibration were assessed by 100x bootstrap resampling. Results: In the non-NST and NST group, 49,631 and 10,154 patients were included, respectively. Age, mode of detection, histology, sublocalisation, grade, pT, pN, hormonal receptor status ± endocrine treatment, HER2 status ± targeted treatment, surgery ± immediate reconstruction ± radiation therapy, and chemotherapy were significant predictors for LRR and/or CBC in non-NST patients. For NST patients this was similar, but excluding (y)pT and (y)pN status, and including presence of ductal carcinoma in situ, axillary lymph node dissection and pathologic complete response.For non-NST patients, the Cox and RSF models were integrated in the online tool with 5-year AUCs of 0.77 (95%CI:0.77–0.77) and 0.68 (95%CI:0.67–0.68)] for LRR and CBC prediction, respectively. For NST patients, the RSF model performed best (AUCs 0.77 (95%CI:0.76–0.78) and 0.73 (95%CI:0.69–0.76) for LRR and CBC, respectively). Regarding calibration, observed-predicted differences were all <1 %. Conclusion: This INFLUENCE 3.0 models showed moderate performance in LRR and CBC prediction. The models have been made available as online tool to enable clinical decision support regarding personalised follow-up. |
| format | Article |
| id | doaj-art-2694b70dbad34b3ab649535c9ac0aeed |
| institution | Kabale University |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-2694b70dbad34b3ab649535c9ac0aeed2025-02-12T05:30:30ZengElsevierBreast1532-30802025-02-0179103829The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapyM.C. Van Maaren0T.A. Hueting1D.J.P. van Uden2M. van Hezewijk3L. de Munck4M.A.M. Mureau5P.A. Seegers6Q.J.M. Voorham7M.K. Schmidt8G.S. Sonke9C.G.M. Groothuis-Oudshoorn10S. Siesling11Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands; Corresponding author. Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands.Evidencio Medical Decision Support, Haaksbergen, the NetherlandsDepartment of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, the NetherlandsRadiotherapiegroep, Institution for Radiation Oncology, Arnhem, the NetherlandsDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the NetherlandsDepartment of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the NetherlandsPalga Foundation, Houten, the NetherlandsPalga Foundation, Houten, the NetherlandsDivision of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the NetherlandsDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the NetherlandsDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the NetherlandsBackground: Individual risk prediction of 5-year locoregional recurrence (LRR) and contralateral breast cancer (CBC) supports decisions regarding personalised surveillance. The previously developed INFLUENCE tool was rebuild, including a recent population and patients who received neoadjuvant systemic therapy (NST). Methods: Women, surgically treated for nonmetastatic breast cancer, diagnosed between 2012 and 2016, were selected from the Netherlands Cancer Registry. Cox regression with restricted cubic splines was compared to Random Survival Forest (RSF) to predict five-year LRR and CBC risks. Separate models were developed for NST patients. Discrimination and calibration were assessed by 100x bootstrap resampling. Results: In the non-NST and NST group, 49,631 and 10,154 patients were included, respectively. Age, mode of detection, histology, sublocalisation, grade, pT, pN, hormonal receptor status ± endocrine treatment, HER2 status ± targeted treatment, surgery ± immediate reconstruction ± radiation therapy, and chemotherapy were significant predictors for LRR and/or CBC in non-NST patients. For NST patients this was similar, but excluding (y)pT and (y)pN status, and including presence of ductal carcinoma in situ, axillary lymph node dissection and pathologic complete response.For non-NST patients, the Cox and RSF models were integrated in the online tool with 5-year AUCs of 0.77 (95%CI:0.77–0.77) and 0.68 (95%CI:0.67–0.68)] for LRR and CBC prediction, respectively. For NST patients, the RSF model performed best (AUCs 0.77 (95%CI:0.76–0.78) and 0.73 (95%CI:0.69–0.76) for LRR and CBC, respectively). Regarding calibration, observed-predicted differences were all <1 %. Conclusion: This INFLUENCE 3.0 models showed moderate performance in LRR and CBC prediction. The models have been made available as online tool to enable clinical decision support regarding personalised follow-up.http://www.sciencedirect.com/science/article/pii/S0960977624001607Breast cancerFollow-upSurveillancePredictionLocoregional recurrenceContralateral breast cancer |
| spellingShingle | M.C. Van Maaren T.A. Hueting D.J.P. van Uden M. van Hezewijk L. de Munck M.A.M. Mureau P.A. Seegers Q.J.M. Voorham M.K. Schmidt G.S. Sonke C.G.M. Groothuis-Oudshoorn S. Siesling The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy Breast Breast cancer Follow-up Surveillance Prediction Locoregional recurrence Contralateral breast cancer |
| title | The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy |
| title_full | The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy |
| title_fullStr | The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy |
| title_full_unstemmed | The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy |
| title_short | The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy |
| title_sort | influence 3 0 model updated predictions of locoregional recurrence and contralateral breast cancer now also suitable for patients treated with neoadjuvant systemic therapy |
| topic | Breast cancer Follow-up Surveillance Prediction Locoregional recurrence Contralateral breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S0960977624001607 |
| work_keys_str_mv | AT mcvanmaaren theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT tahueting theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT djpvanuden theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mvanhezewijk theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT ldemunck theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mammureau theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT paseegers theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT qjmvoorham theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mkschmidt theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT gssonke theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT cgmgroothuisoudshoorn theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT ssiesling theinfluence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mcvanmaaren influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT tahueting influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT djpvanuden influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mvanhezewijk influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT ldemunck influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mammureau influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT paseegers influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT qjmvoorham influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT mkschmidt influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT gssonke influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT cgmgroothuisoudshoorn influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy AT ssiesling influence30modelupdatedpredictionsoflocoregionalrecurrenceandcontralateralbreastcancernowalsosuitableforpatientstreatedwithneoadjuvantsystemictherapy |